Deciphering Age-Dependent ECM Remodelling in Liver: Proteomic Profiling and Its Implications for Aging and Therapeutic Targets

Abstract

Aging is characterised by progressive structural and functional changes in the liver, with the extracellular matrix (ECM) playing a key role in modulating these changes. Our study presents a comprehensive proteomic analysis of the liver ECM across different age stages, uncovering significant age-related changes. Through the identification of 158 ECM proteins in decellularised rat liver scaffolds, we reveal the intricate relationship between ECM composition and liver maturation, as well as the decrease in regenerative capacity. Lumican was identified as a critical regulator with heightened expression in neonatal livers, which is associated with enhanced hepatocyte proliferation and maintenance of stem cell characteristics. Temporal expression analysis distinguished four distinct clusters of ECM proteins, each reflecting the liver's functional evolution from early development to old age. Early developmental stages were marked by proteins essential for liver growth, while adulthood was characterised by a robust ECM supporting metabolic functions. Middle age showed a regulatory shift towards protease balance, and later life was associated with haemostasis-related processes. Our findings underscore the multifaceted role of the ECM in liver health and aging, offering potential opportunities for therapeutic intervention to counteract age-induced liver dysfunction. This study provides a foundational understanding of ECM dynamics in liver aging and sets the stage for the development of innovative strategies to mitigate the effects of age-related liver decline.

Keywords

extracellular matrix (ECM) / liver aging / Lumican / Matrisome / proteomics

References

[1] C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “The Hallmarks of Aging,” Cell 153, no. 6 (2013): 1194-1217.

[2] C. López-Otín, F. Pietrocola, D. Roiz-Valle, L. Galluzzi, and G. Kroemer, “Meta-Hallmarks of Aging and Cancer,” Cell Metabolism 35, no. 1 (2023): 12-35.

[3] J. Ren, M. Song, W. Zhang, et al., “The Aging Biomarker Consortium Represents a New Era for Aging Research in China,” Nature Medicine 29, no. 9 (2023): 2162-2165.

[4] V. Suryadevara, A. D. Hudgins, A. Rajesh, et al., “SenNet Recommendations for Detecting Senescent Cells in Different Tissues,” Nature Reviews. Molecular Cell Biology 25 (2024): 1001-1023.

[5] I. M. Arias, H. J. Alter, J. L. Boyer, et al., The Liver: Biology and Pathobiology (John Wiley & Sons, 2020).

[6] D. Sanfeliu-Redondo, A. Gibert-Ramos, and J. Gracia-Sancho, “Cell Senescence in Liver Diseases: Pathological Mechanism and Theranostic Opportunity,” Nature Reviews. Gastroenterology & Hepatology 21, no. 7 (2024): 477-492.

[7] Consortium, A. B, M. Jiang, Z. Zheng, et al., “A Biomarker Framework for Liver Aging: The Aging Biomarker Consortium Consensus Statement,” Lifestyle Medicine 3, no. 1 (2024): lnae004.

[8] Y. Gao, W. Zhang, L.-Q. Zeng, et al., “Exercise and Dietary Intervention Ameliorate High-Fat Diet-Induced NAFLD and Liver Aging by Inducing Lipophagy,” Redox Biology 36 (2020): 101635.

[9] L. Partridge, M. Fuentealba, and B. K. Kennedy, “The Quest to Slow Ageing Through Drug Discovery,” Nature Reviews Drug Discovery 19, no. 8 (2020): 513-532.

[10] K. Du, L. Wang, J. H. Jun, et al., “Aging Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease by Inducing Ferroptotic Stress,” Nature Aging 4, no. 7 (2024): 949-968.

[11] S. Yang, C. Liu, M. Jiang, et al., “A Single-Nucleus Transcriptomic Atlas of Primate Liver Aging Uncovers the Pro-Senescence Role of SREBP2 in Hepatocytes,” Protein & Cell 15, no. 2 (2024): 98-120.

[12] A. K. Palmer, B. Gustafson, J. L. Kirkland, and U. Smith, “Cellular Senescence: At the Nexus Between Ageing and Diabetes,” Diabetologia 62, no. 10 (2019): 1835-1841.

[13] G. Kroemer, A. B. Maier, A. M. Cuervo, et al., “From Geroscience to Precision Geromedicine: Understanding and Managing Aging,” Cell 188, no. 8 (2025): 2043-2062.

[14] A. D. Theocharis, S. S. Skandalis, C. Gialeli, and N. K. Karamanos, “Extracellular matrix structure,” Advanced Drug Delivery Reviews 97 (2016): 4-27.

[15] J. Liu, Q. Song, W. Yin, et al., “Bioactive Scaffolds for Tissue Engineering: A Review of Decellularized Extracellular Matrix Applications and Innovations,” Exploration 5, no. 1 (2024): 20230078.

[16] P. Lu, V. M. Weaver, and Z. Werb, “The Extracellular Matrix: A Dynamic Niche in Cancer Progression,” Journal of Cell Biology 196, no. 4 (2012): 395-406.

[17] T. R. Cox and J. T. Erler, “Remodeling and Homeostasis of the Extracellular Matrix: Implications for Fibrotic Diseases and Cancer,” Disease Models & Mechanisms 4, no. 2 (2011): 165-178.

[18] W. Chen, Y. Sun, S. Chen, et al., “Matrisome Gene-Based Subclassification of Patients With Liver Fibrosis Identifies Clinical and Molecular Heterogeneities,” Hepatology 78, no. 4 (2023): 1118-1132.

[19] M. B. Goldring and K. B. Marcu, “Cartilage Homeostasis in Health and Rheumatic Diseases,” Arthritis Research & Therapy 11, no. 3 (2009): 224.

[20] N. G. Frangogiannis, “Cardiac Fibrosis: Cell Biological Mechanisms, Molecular Pathways and Therapeutic Opportunities,” Molecular Aspects of Medicine 65 (2019): 70-99.

[21] J. G. Travers, F. A. Kamal, J. Robbins, K. E. Yutzey, and B. C. Blaxall, “Cardiac Fibrosis: The Fibroblast Awakens,” Circulation Research 118, no. 6 (2016): 1021-1040.

[22] R. Li, J. Liu, J. Ma, et al., “Fibrinogen Improves Liver Function via Promoting Cell Aggregation and Fibronectin Assembly in Hepatic Spheroids,” Biomaterials 280 (2022): 121266.

[23] J. Campisi, P. Kapahi, G. J. Lithgow, S. Melov, J. C. Newman, and E. Verdin, “From Discoveries in Ageing Research to Therapeutics for Healthy Ageing,” Nature 571, no. 7764 (2019): 183-192.

[24] Y. Wang, C.-B. Cui, M. Yamauchi, et al., “Lineage Restriction of Human Hepatic Stem Cells to Mature Fates Is Made Efficient by Tissue-Specific Biomatrix Scaffolds,” Hepatology (Baltimore, Md.) 53, no. 1 (2011): 293-305.

[25] R. O. Hynes and A. Naba, “Overview of the Matrisome-An Inventory of Extracellular Matrix Constituents and Functions,” Cold Spring Harbor Perspectives in Biology 4, no. 1 (2012): a004903.

[26] A. Naba, K. R. Clauser, S. Hoersch, H. Liu, S. A. Carr, and R. O. Hynes, “The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices,” Molecular and Cellular Proteomics: MCP 11, no. 4 (2012): M111.014647.

[27] R. P. Aryal, M. Noel, J. Zeng, et al., “Cosmc Regulates O-Glycan Extension in Murine Hepatocytes,” Glycobiology 34, no. 10 (2024): cwae069.

[28] R. Mohallem, A. J. Schaser, and U. K. Aryal, “Proteomic and Phosphoproteomic Signatures of Aging Mouse Liver,” GeroScience 10, no. 3 (2025): s11357.

[29] C. Lyu, W. Kong, Z. Liu, et al., “Advanced Glycation End-Products as Mediators of the Aberrant Crosslinking of Extracellular Matrix in Scarred Liver Tissue,” Nature Biomedical Engineering 7, no. 11 (2023): 1437-1454.

[30] P. Zhao, T. Sun, C. Lyu, et al., “Scar-Degrading Endothelial Cells as a Treatment for Advanced Liver Fibrosis,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 10, no. 4 (2023): e2203315.

[31] Y. Wu, Y. Cao, K. Xu, et al., “Dynamically Remodeled Hepatic Extracellular Matrix Predicts Prognosis of Early-Stage Cirrhosis,” Cell Death & Disease 12, no. 2 (2021): 163.

[32] R.-H. Yuan, C.-L. Hsu, Y.-L. Jhuang, Y.-R. Liu, T.-H. Hsieh, and Y.-M. Jeng, “Tumor-Matrix Interaction Induces Phenotypic Switching in Liver Cancer Cells,” Hepatology International 16, no. 3 (2022): 562-576.

[33] J. Oh, C. S. Kim, M. Kim, W. Jo, Y. H. Sung, and J. Park, “Type VI Collagen and Its Cleavage Product, Endotrophin, Cooperatively Regulate the Adipogenic and Lipolytic Capacity of Adipocytes,” Metabolism 114 (2021): 154430.

[34] C. Gan, U. Yaqoob, J. Lu, et al., “Liver Sinusoidal Endothelial Cells Contribute to Portal Hypertension Through Collagen Type IV-Driven Sinusoidal Remodeling,” JCI Insight 9, no. 11 (2024): e174775.

[35] A. Kyrönlahti, N. Godbole, O. Akinrinade, et al., “Evolving up-Regulation of Biliary Fibrosis-Related Extracellular Matrix Molecules After Successful Portoenterostomy,” Hepatology Communications 5, no. 6 (2021): 1036-1050.

[36] P. Das, M. D. DiVito, J. A. Wertheim, and L. P. Tan, “Collagen-I and Fibronectin Modified Three-Dimensional Electrospun PLGA Scaffolds for Long-Term In Vitro Maintenance of Functional Hepatocytes,” Materials Science & Engineering. C, Materials for Biological Applications 111 (2020): 110723.

[37] A. Acun, R. Oganesyan, K. Uygun, H. Yeh, M. L. Yarmush, and B. E. Uygun, “Liver Donor Age Affects Hepatocyte Function Through Age-Dependent Changes in Decellularized Liver Matrix,” Biomaterials 270 (2021): 120689.

[38] M. N. Sundaram, U. Mony, P. K. Varma, and J. Rangasamy, “Vasoconstrictor and Coagulation Activator Entrapped Chitosan Based Composite Hydrogel for Rapid Bleeding Control,” Carbohydrate Polymers 258 (2021): 117634.

[39] Q. Wang, Y. Feng, A. Wang, et al., “Innovations in 3D Bioprinting and Biomaterials for Liver Tissue Engineering: Paving the Way for Tissue-Engineered Liver,” iLIVER 3, no. 1 (2024): 100080.

[40] E. Armingol, A. Officer, O. Harismendy, and N. E. Lewis, “Deciphering Cell-Cell Interactions and Communication From Gene Expression,” Nature Reviews. Genetics 22, no. 2 (2021): 71-88.

[41] C. Ding, Y. Li, F. Guo, et al., “A Cell-Type-Resolved Liver Proteome,” Molecular & Cellular Proteomics 15, no. 10 (2016): 3190-3202.

[42] L. Liu, W. Michowski, A. Kolodziejczyk, and P. Sicinski, “The Cell Cycle in Stem Cell Proliferation, Pluripotency and Differentiation,” Nature Cell Biology 21, no. 9 (2019): 1060-1067.

[43] F. Li, Y. Ge, D. Liu, and Z. Songyang, “The Role of Telomere-Binding Modulators in Pluripotent Stem Cells,” Protein & Cell 11, no. 1 (2020): 60-70.

[44] K. Wuputra, C. C. Ku, D. C. Wu, Y. C. Lin, S. Saito, and K. K. Yokoyama, “Prevention of Tumor Risk Associated With the Reprogramming of Human Pluripotent Stem Cells,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 100.

[45] N. T. Lam, I. Tandon, and K. Balachandran, “The Role of Fibroblast Growth Factor 1 and 2 on the Pathological Behavior of Valve Interstitial Cells in a Three-Dimensional Mechanically-Conditioned Model,” Journal of Biological Engineering 13 (2019): 45.

[46] C. Deng, Z. Zhang, F. Xu, et al., “Thyroid Hormone Enhances Stem Cell Maintenance and Promotes Lineage-Specific Differentiation in Human Embryonic Stem Cells,” Stem Cell Research & Therapy 13, no. 1 (2022): 120.

[47] L. Wang, X. Mao, X. Yu, et al., “FPR3 Reprograms Glycolytic Metabolism and Stemness in Gastric Cancer via Calcium-NFATc1 Pathway,” Cancer Letters 593 (2024): 216841.

[48] M. De Marzio, A. Kılıç, E. Maiorino, et al., “Genomic Signatures of the Unjamming Transition in Compressed Human Bronchial Epithelial Cells,” Science Advances 7, no. 30 (2021): eabf1088.

[49] A. I. Bachir, A. R. Horwitz, W. J. Nelson, and J. M. Bianchini, “Actin-Based Adhesion Modules Mediate Cell Interactions With the Extracellular Matrix and Neighboring Cells,” Cold Spring Harbor Perspectives in Biology 9, no. 7 (2017): a023234.

[50] X. Liao, X. Li, and R. Liu, “Extracellular-Matrix Mechanics Regulate Cellular Metabolism: A Ninja Warrior Behind Mechano-Chemo Signaling Crosstalk,” Reviews in Endocrine & Metabolic Disorders 24, no. 2 (2023): 207-220.

[51] G. Cen, L. Liu, J. Wang, et al., “Weighted Gene co-Expression Network Analysis to Identify Potential Biological Processes and Key Genes in COVID-19-Related Stroke,” Oxidative Medicine and Cellular Longevity 2022 (2022): 4526022.

[52] H. Fang, X. Xie, P. Liu, et al., “Ziyuglycoside II Alleviates Cyclophosphamide-Induced Leukopenia in Mice via Regulation of HSPC Proliferation and Differentiation,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 132 (2020): 110862.

[53] S. Lubrano, R. D. Cervantes-Villagrana, F. Faraji, et al., “FAK Inhibition Combined With the RAF-MEK Clamp Avutometinib Overcomes Resistance to Targeted and Immune Therapies in BRAF V600E Melanoma,” Cancer Cell 43, no. 3 (2025): 428-445.e6.

[54] S. Yang, M. Wang, D. Tian, et al., “DNA-Functionalized Artificial Mechanoreceptor for de Novo Force-Responsive Signaling,” Nature Chemical Biology 20, no. 8 (2024): 1066-1077.

[55] P. Bella, A. Farini, S. Banfi, et al., “Blockade of IGF2R Improves Muscle Regeneration and Ameliorates Duchenne Muscular Dystrophy,” EMBO Molecular Medicine 12, no. 1 (2020): e11019.

[56] Y. Torrente, P. Bella, L. Tripodi, C. Villa, and A. Farini, “Role of Insulin-Like Growth Factor Receptor 2 Across Muscle Homeostasis: Implications for Treating Muscular Dystrophy,” Cells 9, no. 2 (2020): 441.

[57] X. Guo, X. Fan, C. Xie, A. E. Afe, Y. Yang, and R. Zhou, “Suppressing IGF2R Mitigates Hypoxia-Induced Apoptosis by Reducing the Expression of Pro-Apoptotic Factor BAX,” International Journal of Biological Macromolecules 284, no. Pt 1 (2025): 137785.

[58] H. Shen, P. Gan, K. Wang, et al., “Mononuclear Diploid Cardiomyocytes Support Neonatal Mouse Heart Regeneration in Response to Paracrine IGF2 Signaling,” eLife 9 (2020): 9.

[59] K. Gasbarrino, H. Zheng, A. Hafiane, J. P. Veinot, C. Lai, and S. S. Daskalopoulou, “Decreased Adiponectin-Mediated Signaling Through the AdipoR2 Pathway Is Associated With Carotid Plaque Instability,” Stroke 48, no. 4 (2017): 915-924.

[60] G. Sun, Y. You, H. Li, et al., “Discovery of AdipoRon Analogues as Novel AMPK Activators Without Inhibiting Mitochondrial Complex I,” European Journal of Medicinal Chemistry 200 (2020): 112466.

[61] H. Li, U.-H. Kim, J.-H. Yoon, et al., “Suppression of Hyperglycemia and Hepatic Steatosis by Black-Soybean-Leaf Extract via Enhanced Adiponectin-Receptor Signaling and AMPK Activation,” Journal of Agricultural and Food Chemistry 67, no. 1 (2019): 90-101.

[62] C. P. Monckton, A. Brougham-Cook, G. H. Underhill, and S. R. Khetani, “Modulation of Human iPSC-Derived Hepatocyte Phenotype via Extracellular Matrix Microarrays,” Acta Biomaterialia 153 (2022): 216-230.

[63] M. Lu, S. Tao, C. Zhao, et al., “HIF-1α/LTBP2 Axis Activate HSCs to Promote Liver Fibrosis by Interacting With LOXL1 via the ERK Pathway,” Cellular and Molecular Life Sciences: CMLS 82, no. 1 (2025): 161.

[64] D. Vyas, P. M. Baptista, M. Brovold, et al., “Self-Assembled Liver Organoids Recapitulate Hepatobiliary Organogenesis In Vitro,” Hepatology 67, no. 2 (2018): 750-761.

[65] A. Graja, F. Garcia-Carrizo, A.-M. Jank, et al., “Loss of Periostin Occurs in Aging Adipose Tissue of Mice and Its Genetic Ablation Impairs Adipose Tissue Lipid Metabolism,” Aging Cell 17, no. 5 (2018): e12810.

[66] H. Li, J. Zheng, Q. Xu, et al., “Hepatocyte Adenosine Kinase Promotes Excessive Fat Deposition and Liver Inflammation,” Gastroenterology 164, no. 1 (2023): 134-146.

[67] X. Han, Y. Wu, Q. Yang, and G. Cao, “Peroxisome Proliferator-Activated Receptors in the Pathogenesis and Therapies of Liver Fibrosis,” Pharmacology & Therapeutics 222 (2021): 107791.

[68] I. Garcia-Martinez, R. Alen, L. Pereira, et al., “Saturated Fatty Acid-Enriched Small Extracellular Vesicles Mediate a Crosstalk Inducing Liver Inflammation and Hepatocyte Insulin Resistance,” JHEP Reports: Innovation in Hepatology 5, no. 8 (2023): 100756.

[69] B. T. Wesley, A. D. B. Ross, D. Muraro, et al., “Single-Cell Atlas of Human Liver Development Reveals Pathways Directing Hepatic Cell Fates,” Nature Cell Biology 24, no. 10 (2022): 1487-1498.

[70] “Aging Atlas: A Multi-Omics Database for Aging Biology,” Nucleic Acids Research 49, no. D1 (2021): D825-D830.

[71] M. Franchi, Z. Piperigkou, N. S. Mastronikolis, and N. Karamanos, “Extracellular Matrix Biomechanical Roles and Adaptation in Health and Disease,” FEBS Journal 291, no. 3 (2024): 430-440.

[72] T. A. H. Järvinen and E. Ruoslahti, “Generation of a Multi-Functional, Target Organ-Specific, Anti-Fibrotic Molecule by Molecular Engineering of the Extracellular Matrix Protein, Decorin,” British Journal of Pharmacology 176, no. 1 (2019): 16-25.

[73] P. A. Miguez, E. Bash, M. L. Musskopf, et al., “Control of Tissue Homeostasis by the Extracellular Matrix: Synthetic Heparan Sulfate as a Promising Therapeutic for Periodontal Health and Bone Regeneration,” Periodontology 2000 94, no. 1 (2024): 510-531.

[74] J. S. Chua and B. Kuberan, “Synthetic Xylosides: Probing the Glycosaminoglycan Biosynthetic Machinery for Biomedical Applications,” Accounts of Chemical Research 50, no. 11 (2017): 2693-2705.

[75] C. Colin-Pierre, O. El Baraka, L. Danoux, et al., “Regulation of Stem Cell Fate by HSPGs: Implication in Hair Follicle Cycling,” npj Regenerative Medicine 7, no. 1 (2022): 77.

[76] I. A. Unterweger, J. Klepstad, E. Hannezo, P. R. Lundegaard, A. Trusina, and E. A. Ober, “Lineage Tracing Identifies Heterogeneous Hepatoblast Contribution to Cell Lineages and Postembryonic Organ Growth Dynamics,” PLoS Biology 21, no. 10 (2023): e3002315.

[77] T. Mitaka, N. Ichinohe, and N. Tanimizu, “Small Hepatocytes in the Liver,” Cells 12, no. 23 (2023): 2718.

[78] F. Chen, R. J. Jimenez, K. Sharma, et al., “Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration,” Cell Stem Cell 26, no. 1 (2020): 27-33.

[79] B. Prabhakar, S. Lee, A. Bochanis, W. He, J. E. Manautou, and T. P. Rasmussen, “Lnc-RHL, a Novel Long Non-Coding RNA Required for the Differentiation of Hepatocytes From Human Bipotent Progenitor Cells,” Cell Proliferation 54, no. 2 (2021): e12978.

[80] F. Serrano, M. García-Bravo, M. Blazquez, et al., “Silencing of Hepatic Fate-Conversion Factors Induce Tumorigenesis in Reprogrammed Hepatic Progenitor-Like Cells,” Stem Cell Research & Therapy 7, no. 1 (2016): 96.

[81] D. Tewari, P. Patni, A. Bishayee, A. N. Sah, and A. Bishayee, “Natural Products Targeting the PI3K-Akt-mTOR Signaling Pathway in Cancer: A Novel Therapeutic Strategy,” Seminars in Cancer Biology 80 (2022): 1-17.

[82] Y. Chen, Y. Gong, M. Shi, et al., “miR-3606-3p Alleviates Skin Fibrosis by Integratively Suppressing the Integrin/FAK, p-AKT/p-ERK, and TGF-β Signaling Cascades,” Journal of Advanced Research 24 (2024): S2090-1232.

[83] K. Karamanou, M. Franchi, M. Onisto, A. Passi, D. H. Vynios, and S. Brézillon, “Evaluation of Lumican Effects on Morphology of Invading Breast Cancer Cells, Expression of Integrins and Downstream Signaling,” FEBS Journal 287, no. 22 (2020): 4862-4880.

[84] X. Wang, Q. Zhou, Z. Yu, et al., “Cancer-Associated Fibroblast-Derived Lumican Promotes Gastric Cancer Progression via the Integrin β1-FAK Signaling Pathway,” International Journal of Cancer 141, no. 5 (2017): 998-1010.

[85] E. A. Ober and F. P. Lemaigre, “Development of the Liver: Insights Into Organ and Tissue Morphogenesis,” Journal of Hepatology 68, no. 5 (2018): 1049-1062.

[86] Y. Liang, K. Kaneko, B. Xin, et al., “Temporal Analyses of Postnatal Liver Development and Maturation by Single-Cell Transcriptomics,” Developmental Cell 57, no. 3 (2022): 398-414. e5.

[87] H. Wade, K. Pan, B. Zhang, W. Zheng, and Q. Su, “Mechanistic Role of Long Non-Coding RNAs in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease and Fibrosis,” eGastroenterology 2, no. 4 (2024): e100115.

[88] L. K. Kanninen, R. Harjumäki, P. Peltoniemi, et al., “Laminin-511 and Laminin-521-Based Matrices for Efficient Hepatic Specification of Human Pluripotent Stem Cells,” Biomaterials 103 (2016): 86-100.

[89] W.-C. Hsieh, A. C. Mackinnon, W.-Y. Lu, et al., “Galectin-3 Regulates Hepatic Progenitor Cell Expansion During Liver Injury,” Gut 64, no. 2 (2015): 312-321.

[90] R. Li, J. Liu, J. Ma, et al., “Fibrinogen Improves Liver Function via Promoting Cell Aggregation and Fibronectin Assembly in Hepatic Spheroids,” Biomaterials 280 (2022): 121266.

[91] N. K. Karamanos, Z. Piperigkou, A. D. Theocharis, et al., “Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics,” Chemical Reviews 118, no. 18 (2018): 9152-9232.

[92] M. Marchand, C. Monnot, L. Muller, and S. Germain, “Extracellular Matrix Scaffolding in Angiogenesis and Capillary Homeostasis,” Seminars in Cell & Developmental Biology, Elsevier 89 (2019): 147-156.

[93] T. E. Sutherland, D. P. Dyer, and J. E. Allen, “The Extracellular Matrix and the Immune System: A Mutually Dependent Relationship,” Science 379, no. 6633 (2023): eabp8964.

[94] K. Arnold, Y. Xu, E. M. Sparkenbaugh, et al., “Design of Anti-Inflammatory Heparan Sulfate to Protect Against Acetaminophen-Induced Acute Liver Failure,” Science Translational Medicine 12, no. 535 (2020): eaav8075.

[95] L. Fu, M. Suflita, and R. J. Linhardt, “Bioengineered Heparins and Heparan Sulfates,” Advanced Drug Delivery Reviews 97 (2016): 237-249.

[96] M.-C. Tsui, H.-Y. Liu, H.-S. Chu, et al., “The Versatile Roles of Lumican in Eye Diseases: A Review,” Ocular Surface 29 (2023): 388-397.

[97] E.-M. Giatagana, A. Berdiaki, A. Tsatsakis, G. N. Tzanakakis, and D. Nikitovic, “Lumican in Carcinogenesis—Revisited,” Biomolecules 11, no. 9 (2021): 1319.

[98] K.-J. Liu, K.-C. Hsiao, P.-Y. Chu, and G.-C. Chang, “Elevated Expression of Lumican in Lung Cancer Cells Promotes Bone Metastasis Through an Autocrine Regulatory Mechanism,” Annals of Oncology 30 (2019): vi131.

[99] Z. Guo, Z. Li, M. Chen, et al., “Multi-Omics Analysis Reveals the Prognostic and Tumor Micro-Environmental Value of Lumican in Multiple Cancer Types,” Frontiers in Molecular Biosciences 10 (2023): 1158747.

[100] G. Maiti, J. Frikeche, C. Y.-M. Lam, et al., “Matrix Lumican Endocytosed by Immune Cells Controls Receptor Ligand Trafficking to Promote TLR4 and Restrict TLR9 in Sepsis,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 27 (2021): e2100999118.

[101] S. Saika, Y. Ohnishi, A. Ooshima, C.-Y. Liu, and W. W.-Y. Kao, “Epithelial Repair: Roles of Extracellular Matrix,” Cornea 21 (2002): S23-S29.

[102] K. Karamanou, G. Perrot, F.-X. Maquart, and S. Brézillon, “Lumican as a Multivalent Effector in Wound Healing,” Advanced Drug Delivery Reviews 129 (2018): 344-351.

[103] E. Arriazu, M. Ruiz de Galarreta, F. J. Cubero, et al., “Extracellular Matrix and Liver Disease,” Antioxidants & Redox Signaling 21, no. 7 (2014): 1078-1097.

[104] I. F. Villesen, S. J. Daniels, D. J. Leeming, M. A. Karsdal, and M. J. Nielsen, “The Signalling and Functional Role of the Extracellular Matrix in the Development of Liver Fibrosis,” Alimentary Pharmacology & Therapeutics 52, no. 1 (2020): 85-97.

[105] V. L. Payen, A. Lavergne, N. A. Sarika, et al., “Single-Cell RNA Sequencing of Human Liver Reveals Hepatic Stellate Cell Heterogeneity,” JHEP Reports 3, no. 3 (2021): 100278.

[106] W. He, Q. Wang, X. Tian, and G. Pan, “Recapitulating Dynamic ECM Ligand Presentation at Biomaterial Interfaces: Molecular Strategies and Biomedical Prospects,” Exploration 2, no. 1 (2022): 20210093.

[107] X. Shao, C. D. Gomez, N. Kapoor, et al., “MatrisomeDB 2.0: 2023 Updates to the ECM-Protein Knowledge Database,” Nucleic Acids Research 51, no. D1 (2023): D1519-D1530.

[108] X. Shao, I. N. Taha, K. R. Clauser, Y. Gao, and A. Naba, “MatrisomeDB: The ECM-Protein Knowledge Database,” Nucleic Acids Research 48, no. D1 (2020): D1136-D1144.

[109] Y. Wang, C. B. Cui, M. Yamauchi, et al., “Lineage Restriction of Human Hepatic Stem Cells to Mature Fates Is Made Efficient by Tissue-Specific Biomatrix Scaffolds,” Hepatology 53, no. 1 (2011): 293-305.

[110] Q. Wu, J. Liu, L. Liu, et al., “Establishment of an Ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver,” ACS Biomaterials Science & Engineering 4, no. 8 (2018): 3016-3026.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.